Director/PDMR Shareholding

Summary by AI BETAClose X

Judges Scientific plc announced that Chief Executive Officer Tim Prestidge purchased 641 ordinary shares at 4335 pence per share on April 7, 2026, increasing his beneficial holding to 1,248 shares, representing approximately 0.02% of the company's issued share capital. This transaction, a purchase of ordinary shares on the AIM Market of the London Stock Exchange, is an initial notification and does not involve any aggregated volumes or prices beyond the single transaction.

Disclaimer*

Judges Scientific PLC
07 April 2026
 

7 April 2026

 

Judges Scientific plc

("Judges Scientific" or the "Company")

 

Director/PDMR Shareholding

 

Judges Scientific plc (AIM: JDG), a group focused on acquiring and developing companies in the scientific instrument sector announces that Tim Prestidge, Chief Executive Officer, on 7 April 2026 purchased 641 ordinary shares of 5p each in the Company ("Ordinary Shares") at a price of 4335 pence per share. Following this transaction Tim Prestidge's beneficial holding is now 1,248 Ordinary Shares representing approximately 0.02% of the total issued share capital and voting rights in the Company.

 

For further information please contact: 

 

Judges Scientific plc

David Cicurel, CEO

Brad Ormsby, CFO

Tel: +44 (0) 20 3829 6970

 

 

Shore Capital (Nominated Adviser & Joint Broker)

Stephane Auton

Harry Davies-Ball

Tel: +44 (0) 20 7408 4090

 


Panmure Liberum (Joint Broker)

Edward Mansfield

William King

Tel : +44 (0) 20 3100 2222

 

 

Investec Bank plc (Joint Broker)

Virginia Bull

Carlton Nelson

Tel: +44 (0) 20 7597 4000


Alma (Financial Public Relations)

Sam Modlin

Rebecca Sanders-Hewett

Joe Pederzolli

Sarah Peters

Tel: +44 (0) 20 3405 0205

judges@almastrategic.com



 

Notes to editors:

Judges Scientific plc (AIM: JDG), is a group focused on acquiring and developing companies in the scientific instrument sector.  The Group consists of 25 businesses acquired since 2005.

 

The acquired companies are primarily UK-based with products sold worldwide to a diverse range of markets including higher education institutions, scientific research facilities, manufacturers, and regulatory authorities.  The UK is a recognised centre of excellence for scientific instruments.  The Group has received five Queen's Awards for Innovation and Export.

 

The Group's companies predominantly operate in global niche markets, with long term growth fundamentals and resilient margins.

 

Judges Scientific maintains a policy of selectively acquiring businesses that generate sustainable profits and cash.  Shareholder returns are created through the reduction of debt, organic growth, and dividends.

 

For further information, please visit www.judges.uk.com

 

1

 

Details of the person discharging managerial responsibilities / person closely associated

 

a)

 

Name

 

 

Tim Prestidge

2

 

Reason for the notification

 

a)

 

Position/status

 

 

Chief Executive Officer

b)

 

Initial notification /Amendment

 

 

Initial notification

3

 

Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

 

a)

 

Name

 

 

Judges Scientific plc

b)

 

LEI

 

 

2138004EXWWPTW1JOL31

4

 

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted

 

a)

 

Description of the financial instrument, type of instrument

 

Identification code

 

Ordinary shares in Judges Scientific plc

 

 

GB0032398678

 

b)

 

Nature of the transaction

 

 

Purchase of shares

c)

 

Price(s) and volume(s)

 

 

 

Price(s)

 

Volume(s)

4335p

 

641

d)

 

Aggregated information

 

- Aggregated volume

 

- Price

 

N/A (single transaction)

e)

 

Date of the transaction

 

 

07/04/2026

f)

 

Place of the transaction

 

 

London Stock Exchange, AIM Market (XLON)

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
UK 100

Latest directors dealings